Cowen & Co. Releases a Buy Rating on Clearside Biomedical

By Carrie Williams

In a report released today, Boris Peaker from Cowen & Co. reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares opened today at $7.42.

Peaker said:

“This morning CLSD announced accrual completion of its Phase 1/2 DME trial.”

According to, Peaker is a 3-star analyst with an average return of 2.9% and a 40.7% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, and Merrimack Pharmaceuticals.

Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $24.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which develops drug therapies to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and retina. The company was founded by Samirkumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry Edelhauser in May 2011 and is headquartered in Alpharetta, GA.